Upstream Bio, Inc.UPB

Upstream Bio, Inc. reported collaboration revenue of $1.0 million for the three months ended 31 March 2026, up from $0.6 million in the prior-year period, while its net loss attributable to the parent widened to $40.6 million and operating cash burn reached $47.9 million. The company's SEC 10-Q filing dated 13 May 2026 shows a balance sheet carrying $318.1 million in total assets, including $96.7 million in cash and $197.9 million in short-term investments, against only $14.1 million in total liabilities, leaving stockholders' equity at $304.0 million.

The business is a clinical-stage biotechnology company focused on inflammatory diseases, with an initial emphasis on severe respiratory disorders. Its lead candidate, verekitug, is being developed under a license agreement with Lonza Sales AG that originated from an asset purchase agreement with Astellas Pharma, Inc. in October 2021. Upstream Bio does not yet have a marketed product; it relies entirely on third parties for clinical trials, manufacturing and, if approved, future commercialisation.

Research and development expense consumed $36.6 million of the $43.6 million operating loss during the quarter, reflecting the cost of advancing clinical programmes. Diluted loss per share was $0.75 on a weighted average share count of 54.3 million. The company's cash position, while substantial, is being drawn down at a rate that implies a multi-year runway, but no revenue inflection point is visible in the current filings.

A cluster of insider Form 4 filings appeared on 17 June 2026, signalling active equity management by officers and directors, a governance datapoint that holders should note alongside the company's dependence on Lonza for manufacturing and the broader clinical-trial timeline. The SEC EDGAR index and companyfacts JSON confirm the financial structure, though no new product approvals or phase changes have been publicly filed since the 10-Q.

The source rail for this file includes SEC EDGAR submissions, the 10-Q, an accompanying press release, and ownership filings, but The source-change rail is filing/source-led and does not use chart-derived signals. Chart context is available separately on this page through the Atlas chart snapshot or TradingView route where available. Investors reading the evidence should recognise that the company's value proposition remains entirely contingent on clinical outcomes and regulatory decisions, which are not yet in the public record.